Chemical: Drug
efavirenz

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for efavirenz
  2. EMA Label for efavirenz,emtricitabine,tenofovir and CYP2B6
  3. HCSC Label for efavirenz,emtricitabine,tenofovir and CYP2B6




Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for efavirenz

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2A6 *1A N/A N/A N/A
VIP No VIP available VA CYP2A6 *2 N/A N/A N/A
VIP No VIP available No VIP available CYP2A6 *7 N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *9 N/A N/A N/A
VIP No VIP available No VIP available CYP2A6 *9A N/A N/A N/A
VIP No VIP available No VIP available CYP2A6 *12A N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *17 N/A N/A N/A
VIP No VIP available No VIP available CYP2A6 *1X2A N/A N/A N/A
No VIP available CA VA CYP2B6 *1 N/A N/A N/A
VIP CA VA CYP2B6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *6A N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *9 N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *11A N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *18 N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *26 N/A N/A N/A
No VIP available CA No VIP available CYP2B6 *27 N/A N/A N/A
No VIP available CA VA CYP2B6 *28 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *01:01:01 N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2B6 poor metabolizer genotype N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1042389 NC_000019.10:g.41018248T>C, NC_000019.9:g.41524153T>C, NG_007929.1:g.31950T>C, NM_000767.4:c.*1421T>C, XM_005258571.1:c.*1421T>C, XM_011526548.1:c.*1421T>C, XM_011526549.1:c.*1421T>C, XM_011526550.1:c.*1421T>C, rs3181848, rs57627668
T > C
SNP
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1054190 NC_000003.11:g.119536718C>T, NC_000003.12:g.119817871C>T, NG_011856.1:g.42388C>T, NM_003889.3:c.*659C>T, NM_022002.2:c.*659C>T, NM_033013.2:c.*659C>T, XM_005247866.1:c.995+2040C>T, rs17203829, rs3194719, rs56558716, rs57770599
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1054191 NC_000003.11:g.119536897G>A, NC_000003.12:g.119818050G>A, NG_011856.1:g.42567G>A, NM_003889.3:c.*838G>A, NM_022002.2:c.*838G>A, NM_033013.2:c.*838G>A, XM_005247866.1:c.995+2219G>A, rs17809762, rs17838785, rs3194721, rs57939560
G > A
SNP
No VIP available CA VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available No Clinical Annotations available VA
rs12721655 NC_000019.10:g.41004377A>G, NC_000019.9:g.41510282A>G, NG_007929.1:g.18079A>G, NM_000767.4:c.415A>G, NP_000758.1:p.Lys139Glu, XM_005258569.1:c.415A>G, XM_005258569.3:c.415A>G, XM_005258570.1:c.415A>G, XM_005258571.1:c.295A>G, XM_006723050.2:c.415A>G, XM_011526546.1:c.415A>G, XM_011526547.1:c.415A>G, XM_011526548.1:c.415A>G, XM_011526549.1:c.-145A>G, XM_011526550.1:c.295A>G, XP_005258626.1:p.Lys139Glu, XP_005258627.1:p.Lys139Glu, XP_005258628.1:p.Lys99Glu, XP_006723113.1:p.Lys139Glu, XP_011524848.1:p.Lys139Glu, XP_011524849.1:p.Lys139Glu, XP_011524850.1:p.Lys139Glu, XP_011524852.1:p.Lys99Glu, rs56006122
A > G
SNP
K139E
No VIP available No Clinical Annotations available VA
rs1517618 NC_000015.10:g.92104415G>C, NC_000015.9:g.92647645G>C, NM_001145044.1:c.882G>C, NM_013272.3:c.882G>C, NP_001138516.1:p.Glu294Asp, NP_037404.2:p.Glu294Asp, XM_005254889.1:c.882G>C, XM_005254890.1:c.708G>C, XM_005254891.1:c.537G>C, XM_011521456.1:c.708G>C, XM_011521457.1:c.882G>C, XP_005254946.1:p.Glu294Asp, XP_005254947.1:p.Glu236Asp, XP_005254948.1:p.Glu179Asp, XP_011519758.1:p.Glu236Asp, XP_011519759.1:p.Glu294Asp, XR_429450.2:n.802G>C, XR_931795.1:n.972G>C, XR_931796.1:n.972G>C, rs17519193, rs17844850, rs17857564, rs52834221, rs60307785
G > C
SNP
E294D
No VIP available CA VA
rs1800896 NC_000001.10:g.206946897T>C, NC_000001.11:g.206773552T>C, NG_012088.1:g.3943A>G, NM_000572.2:c.-1117A>G, XM_011509506.1:c.-1001-116A>G, rs36213835, rs386545607, rs59915840
T > C
SNP
No VIP available CA VA
rs1884613 NC_000020.10:g.42980415C>G, NC_000020.11:g.44351775C>G, NG_009818.1:g.975C>G, XR_936745.1:n.486+93G>C, XR_936746.1:n.490+93G>C, XR_936747.1:n.405+93G>C, XR_936748.1:n.278+93G>C, XR_936749.1:n.490+93G>C, XR_936750.1:n.285+93G>C
C > G
SNP
No VIP available CA VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available CA VA
rs2231142 NC_000004.11:g.89052323G>T, NC_000004.12:g.88131171G>T, NG_032067.2:g.105152C>A, NM_001257386.1:c.421C>A, NM_004827.2:c.421C>A, NP_001244315.1:p.Gln141Lys, NP_004818.2:p.Gln141Lys, XM_005263354.1:c.421C>A, XM_005263354.2:c.421C>A, XM_005263355.1:c.421C>A, XM_005263355.2:c.421C>A, XM_005263356.1:c.421C>A, XM_005263356.2:c.421C>A, XM_011532420.1:c.421C>A, XP_005263411.1:p.Gln141Lys, XP_005263412.1:p.Gln141Lys, XP_005263413.1:p.Gln141Lys, XP_011530722.1:p.Gln141Lys, rs12721641, rs28365035, rs3736117, rs52809243, rs58973676
G > T
SNP
Q141K
No VIP available No Clinical Annotations available VA
rs2274407 NC_000013.10:g.95859035C>A, NC_000013.11:g.95206781C>A, NM_001105515.2:c.912G>T, NM_001301829.1:c.912G>T, NM_001301830.1:c.687G>T, NM_005845.4:c.912G>T, NP_001098985.1:p.Lys304Asn, NP_001288758.1:p.Lys304Asn, NP_001288759.1:p.Lys229Asn, NP_005836.2:p.Lys304Asn, XM_005254025.1:c.783G>T, XM_005254025.2:c.783G>T, XM_005254026.1:c.912G>T, XM_005254027.1:c.687G>T, XM_005254028.1:c.687G>T, XM_006719914.1:c.912G>T, XM_011521047.1:c.363G>T, XP_005254082.1:p.Lys261Asn, XP_005254083.1:p.Lys304Asn, XP_005254084.1:p.Lys229Asn, XP_005254085.1:p.Lys229Asn, XP_006719977.1:p.Lys304Asn, XP_011519349.1:p.Lys121Asn, rs117944872, rs52813831, rs58221897
C > A
SNP
K304N
No VIP available CA VA
rs2279343 NC_000019.10:g.41009358A>G, NC_000019.9:g.41515263A>G, NG_007929.1:g.23060A>G, NM_000767.4:c.785A>G, NP_000758.1:p.Lys262Arg, XM_005258569.1:c.785A>G, XM_005258569.3:c.785A>G, XM_005258570.1:c.785A>G, XM_005258571.1:c.365-2940A>G, XM_006723050.2:c.785A>G, XM_011526546.1:c.785A>G, XM_011526547.1:c.785A>G, XM_011526548.1:c.485-2940A>G, XM_011526549.1:c.194A>G, XM_011526550.1:c.365-2940A>G, XP_005258626.1:p.Lys262Arg, XP_005258627.1:p.Lys262Arg, XP_006723113.1:p.Lys262Arg, XP_011524848.1:p.Lys262Arg, XP_011524849.1:p.Lys262Arg, XP_011524851.1:p.Lys65Arg
A > G
SNP
K262R
No VIP available CA VA
rs2279345 NC_000019.10:g.41009797T>C, NC_000019.9:g.41515702T>C, NG_007929.1:g.23499T>C, NM_000767.4:c.823-197T>C, XM_005258569.1:c.823-197T>C, XM_005258569.3:c.823-197T>C, XM_005258570.1:c.823-197T>C, XM_005258571.1:c.365-2501T>C, XM_006723050.2:c.823-197T>C, XM_011526546.1:c.823-197T>C, XM_011526547.1:c.823-197T>C, XM_011526548.1:c.485-2501T>C, XM_011526549.1:c.232-197T>C, XM_011526550.1:c.365-2501T>C, rs111133571, rs17713554, rs28969412, rs41314922, rs45631888, rs52823712, rs60560431
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2307024 NC_000012.11:g.22005003T>G, NC_000012.12:g.21852069T>G, NG_012819.1:g.89626A>C, NM_005691.2:c.2769+28A>C, NM_005691.3:c.2769+28A>C, NM_020297.2:c.2769+28A>C, NM_020297.3:c.2769+28A>C, XM_005253284.1:c.2769+28A>C, XM_005253284.2:c.2769+28A>C, XM_005253285.1:c.2769+28A>C, XM_005253286.1:c.2769+28A>C, XM_005253286.2:c.2769+28A>C, XM_005253287.1:c.2769+28A>C, XM_005253287.3:c.2769+28A>C, XM_005253288.1:c.2769+28A>C, XM_005253288.2:c.2769+28A>C, XM_005253289.1:c.2730+28A>C, XM_005253289.2:c.2730+28A>C, XM_005253290.1:c.2628+28A>C, XM_005253290.2:c.2628+28A>C, XM_005253291.1:c.2769+28A>C, XM_006719025.2:c.2730+28A>C, XM_011520545.1:c.2769+28A>C, rs59476731
T > G
SNP
No VIP available CA VA
rs2307424 NC_000001.10:g.161202605G>A, NC_000001.11:g.161232815G>A, NG_029113.1:g.10396C>T, NM_001077469.2:c.540C>T, NM_001077470.2:c.453C>T, NM_001077471.2:c.540C>T, NM_001077472.2:c.453C>T, NM_001077473.2:c.453C>T, NM_001077474.2:c.540C>T, NM_001077475.2:c.453C>T, NM_001077476.2:c.453C>T, NM_001077477.2:c.453C>T, NM_001077478.2:c.540C>T, NM_001077479.2:c.453C>T, NM_001077480.2:c.540C>T, NM_001077481.2:c.540C>T, NM_001077482.2:c.540C>T, NM_005122.4:c.540C>T, NP_001070937.1:p.Pro180=, NP_001070938.1:p.Pro151=, NP_001070939.1:p.Pro180=, NP_001070940.1:p.Pro151=, NP_001070941.1:p.Pro151=, NP_001070942.1:p.Pro180=, NP_001070943.1:p.Pro151=, NP_001070944.1:p.Pro151=, NP_001070945.1:p.Pro151=, NP_001070946.1:p.Pro180=, NP_001070947.1:p.Pro151=, NP_001070948.1:p.Pro180=, NP_001070949.1:p.Pro180=, NP_001070950.1:p.Pro180=, NP_005113.1:p.Pro180=, XM_005245693.1:c.756C>T, XM_005245693.3:c.756C>T, XM_005245694.1:c.756C>T, XM_005245694.3:c.756C>T, XM_005245695.1:c.756C>T, XM_005245696.1:c.666C>T, XM_005245697.1:c.540C>T, XM_005245697.3:c.540C>T, XM_005245698.1:c.455-1341C>T, XM_005245699.1:c.455-1341C>T, XM_011510237.1:c.756C>T, XP_005245750.1:p.Pro252=, XP_005245751.1:p.Pro252=, XP_005245752.1:p.Pro252=, XP_005245753.1:p.Pro222=, XP_005245754.1:p.Pro180=, XP_011508539.1:p.Pro252=, rs58418822
G > A
SNP
P180P
No VIP available No Clinical Annotations available VA
rs2502815 NC_000001.10:g.161203227G>A, NC_000001.11:g.161233437G>A, NG_029113.1:g.9774C>T, NM_001077469.2:c.239-99C>T, NM_001077470.2:c.152-99C>T, NM_001077471.2:c.239-99C>T, NM_001077472.2:c.152-99C>T, NM_001077473.2:c.152-99C>T, NM_001077474.2:c.239-99C>T, NM_001077475.2:c.152-99C>T, NM_001077476.2:c.152-99C>T, NM_001077477.2:c.152-99C>T, NM_001077478.2:c.239-99C>T, NM_001077479.2:c.152-99C>T, NM_001077480.2:c.239-99C>T, NM_001077481.2:c.239-99C>T, NM_001077482.2:c.239-99C>T, NM_005122.4:c.239-99C>T, XM_005245693.1:c.455-99C>T, XM_005245693.3:c.455-99C>T, XM_005245694.1:c.455-99C>T, XM_005245694.3:c.455-99C>T, XM_005245695.1:c.455-99C>T, XM_005245696.1:c.455-99C>T, XM_005245697.1:c.239-99C>T, XM_005245697.3:c.239-99C>T, XM_005245698.1:c.455-1963C>T, XM_005245699.1:c.455-1963C>T, XM_011510237.1:c.455-99C>T, rs58399464
G > A
SNP
No VIP available CA VA
rs2740574 NC_000007.13:g.99382096C>T, NC_000007.14:g.99784473C>T, NG_008421.1:g.4713G>A, NM_001202855.2:c.-392G>A, NM_017460.5:c.-392G>A, XM_011515841.1:c.-392G>A, XM_011515842.1:c.-392G>A, rs3176920, rs36231114, rs59393892
C > T
SNP
No VIP available CA VA
rs28365062 NC_000004.11:g.69964271A>G, NC_000004.12:g.69098553A>G, NM_001074.2:c.735A>G, NP_001065.2:p.Thr245=, XM_005265702.1:c.-13A>G, XM_005265702.2:c.-13A>G, XM_011532229.1:c.735A>G, XM_011532230.1:c.735A>G, XM_011532231.1:c.-13A>G, XP_011530531.1:p.Thr245=, XP_011530532.1:p.Thr245=, rs58136729
A > G
SNP
T245T
No VIP available No Clinical Annotations available VA
rs28371759 NC_000007.13:g.99361626A>G, NC_000007.14:g.99764003A>G, NG_008421.1:g.25183T>C, NM_001202855.2:c.875T>C, NM_017460.5:c.878T>C, NP_001189784.1:p.Leu292Pro, NP_059488.2:p.Leu293Pro, XM_011515841.1:c.878T>C, XM_011515842.1:c.875T>C, XP_011514143.1:p.Leu293Pro, XP_011514144.1:p.Leu292Pro, rs386574775, rs60608883
A > G
SNP
L292P
No VIP available CA VA
rs28399433 NC_000019.10:g.40850474A>C, NC_000019.9:g.41356379A>C, NG_008377.1:g.4974T>G, NM_000762.5:c.-48T>G, XM_005258568.1:c.-48T>G, rs386508632, rs58538938
A > C
SNP
No VIP available CA VA
rs28399454 NC_000019.10:g.40845362C>T, NC_000019.9:g.41351267C>T, NG_008377.1:g.10086G>A, NM_000762.5:c.1093G>A, NP_000753.3:p.Val365Met, XM_005258568.1:c.940G>A, XP_005258625.1:p.Val314Met, rs57673794
C > T
SNP
V365M
rs28399499 NC_000019.10:g.41012316T>C, NC_000019.9:g.41518221T>C, NG_007929.1:g.26018T>C, NM_000767.4:c.983T>C, NP_000758.1:p.Ile328Thr, XM_005258569.1:c.983T>C, XM_005258569.3:c.983T>C, XM_005258570.1:c.983T>C, XM_005258571.1:c.383T>C, XM_006723050.2:c.983T>C, XM_011526546.1:c.983T>C, XM_011526547.1:c.983T>C, XM_011526548.1:c.503T>C, XM_011526549.1:c.392T>C, XM_011526550.1:c.383T>C, XP_005258626.1:p.Ile328Thr, XP_005258627.1:p.Ile328Thr, XP_005258628.1:p.Ile128Thr, XP_006723113.1:p.Ile328Thr, XP_011524848.1:p.Ile328Thr, XP_011524849.1:p.Ile328Thr, XP_011524850.1:p.Ile168Thr, XP_011524851.1:p.Ile131Thr, XP_011524852.1:p.Ile128Thr
T > C
SNP
I328T
No VIP available CA VA
rs2853826
G > A
SNP
No VIP available CA VA
rs3003596 NC_000001.10:g.161204217A>G, NC_000001.11:g.161234427A>G, NG_029113.1:g.8784T>C, NM_001077469.2:c.239-1089T>C, NM_001077470.2:c.152-1089T>C, NM_001077471.2:c.239-1089T>C, NM_001077472.2:c.152-1089T>C, NM_001077473.2:c.152-1089T>C, NM_001077474.2:c.239-1089T>C, NM_001077475.2:c.152-1089T>C, NM_001077476.2:c.152-1089T>C, NM_001077477.2:c.152-1089T>C, NM_001077478.2:c.239-1089T>C, NM_001077479.2:c.152-1089T>C, NM_001077480.2:c.239-1089T>C, NM_001077481.2:c.239-1089T>C, NM_001077482.2:c.239-1089T>C, NM_005122.4:c.239-1089T>C, XM_005245693.1:c.455-1089T>C, XM_005245693.3:c.455-1089T>C, XM_005245694.1:c.455-1089T>C, XM_005245694.3:c.455-1089T>C, XM_005245695.1:c.455-1089T>C, XM_005245696.1:c.455-1089T>C, XM_005245697.1:c.239-1089T>C, XM_005245697.3:c.239-1089T>C, XM_005245698.1:c.454+1420T>C, XM_005245699.1:c.454+1420T>C, XM_011510237.1:c.455-1089T>C
A > G
SNP
No VIP available No Clinical Annotations available VA
rs3211371 NC_000019.10:g.41016810C>T, NC_000019.9:g.41522715C>T, NG_007929.1:g.30512C>T, NM_000767.4:c.1459C>T, NP_000758.1:p.Arg487Cys, XM_005258569.1:c.*48C>T, XM_005258569.3:c.*48C>T, XM_005258570.1:c.*214C>T, XM_005258571.1:c.859C>T, XM_006723050.2:c.*143C>T, XM_011526547.1:c.*214C>T, XM_011526548.1:c.979C>T, XM_011526549.1:c.868C>T, XM_011526550.1:c.859C>T, XP_005258628.1:p.Arg287Cys, XP_011524850.1:p.Arg327Cys, XP_011524851.1:p.Arg290Cys, XP_011524852.1:p.Arg287Cys, rs12721654, rs28399500, rs33995163, rs58951873
C > T
SNP
R487C
No VIP available CA VA
rs35303484 NC_000019.10:g.40991441A>G, NC_000019.9:g.41497346A>G, NG_007929.1:g.5143A>G, NM_000767.4:c.136A>G, NP_000758.1:p.Met46Val, XM_005258569.1:c.136A>G, XM_005258569.3:c.136A>G, XM_005258570.1:c.136A>G, XM_006723050.2:c.136A>G, XM_011526546.1:c.136A>G, XM_011526547.1:c.136A>G, XM_011526548.1:c.136A>G, XP_005258626.1:p.Met46Val, XP_005258627.1:p.Met46Val, XP_006723113.1:p.Met46Val, XP_011524848.1:p.Met46Val, XP_011524849.1:p.Met46Val, XP_011524850.1:p.Met46Val
A > G
SNP
M46V
No VIP available CA VA
rs36118214 NC_000019.10:g.41013401G>A, NC_000019.9:g.41519306G>A, NG_007929.1:g.27103G>A, NM_000767.4:c.1294+586G>A, XM_005258569.1:c.1152+916G>A, XM_005258569.3:c.1152+916G>A, XM_005258570.1:c.*49+371G>A, XM_005258571.1:c.694+586G>A, XM_006723050.2:c.1352+371G>A, XM_011526546.1:c.*487G>A, XM_011526547.1:c.*49+371G>A, XM_011526548.1:c.814+586G>A, XM_011526549.1:c.703+586G>A, XM_011526550.1:c.694+586G>A, rs60761763
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3732360 NC_000003.11:g.119536581C>T, NC_000003.12:g.119817734C>T, NG_011856.1:g.42251C>T, NM_003889.3:c.*522C>T, NM_022002.2:c.*522C>T, NM_033013.2:c.*522C>T, XM_005247866.1:c.995+1903C>T, rs386584908, rs57419996
C > T
SNP
No VIP available No Clinical Annotations available VA
rs374527 NC_000008.10:g.55550927G>T, NC_000008.11:g.54638367G>T, XM_005251278.1:c.218-10618G>T
G > T
SNP
rs3745274 NC_000019.10:g.41006936G>T, NC_000019.9:g.41512841G>T, NG_007929.1:g.20638G>T, NM_000767.4:c.516G>T, NP_000758.1:p.Gln172His, XM_005258569.1:c.516G>T, XM_005258569.3:c.516G>T, XM_005258570.1:c.516G>T, XM_005258571.1:c.364+2490G>T, XM_006723050.2:c.516G>T, XM_011526546.1:c.516G>T, XM_011526547.1:c.516G>T, XM_011526548.1:c.484+2490G>T, XM_011526549.1:c.-75-1G>T, XM_011526550.1:c.364+2490G>T, XP_005258626.1:p.Gln172His, XP_005258627.1:p.Gln172His, XP_006723113.1:p.Gln172His, XP_011524848.1:p.Gln172His, XP_011524849.1:p.Gln172His, rs56308434, rs57685583
G > T
SNP
Q172H
No VIP available No Clinical Annotations available VA
rs3814057 NC_000003.11:g.119537254A>C, NC_000003.12:g.119818407A>C, NG_011856.1:g.42924A>C, NM_003889.3:c.*1195A>C, NM_022002.2:c.*1195A>C, NM_033013.2:c.*1195A>C, XM_005247866.1:c.995+2576A>C
A > C
SNP
No VIP available CA VA
rs3842 NC_000007.13:g.87133366T>C, NC_000007.14:g.87504050T>C, NG_011513.1:g.214199A>G, NM_000927.4:c.*193A>G, rs3747805, rs60395104
T > C
SNP
No VIP available No Clinical Annotations available VA
rs45564134 NC_000015.10:g.74756062delG, NC_000015.9:g.75048403delG, NG_008431.1:g.38521delG, NM_000761.3:c.*974delG, NM_000761.4:c.*974delG
G > -
indel
No VIP available CA VA
rs4803419 NC_000019.10:g.41006887C>T, NC_000019.9:g.41512792C>T, NG_007929.1:g.20589C>T, NM_000767.4:c.485-18C>T, XM_005258569.1:c.485-18C>T, XM_005258569.3:c.485-18C>T, XM_005258570.1:c.485-18C>T, XM_005258571.1:c.364+2441C>T, XM_006723050.2:c.485-18C>T, XM_011526546.1:c.485-18C>T, XM_011526547.1:c.485-18C>T, XM_011526548.1:c.484+2441C>T, XM_011526549.1:c.-75-50C>T, XM_011526550.1:c.364+2441C>T, rs60830962
C > T
SNP
No VIP available No Clinical Annotations available VA
rs628031 NC_000006.11:g.160560845A>G, NC_000006.12:g.160139813A>G, NM_003057.2:c.1222A>G, NM_153187.1:c.1222A>G, NP_003048.1:p.Met408Val, NP_694857.1:p.Met408Val, XM_005267102.1:c.1222A>G, XM_005267102.3:c.1222A>G, XM_005267103.1:c.1222A>G, XM_005267104.1:c.646A>G, XM_005267104.3:c.646A>G, XM_005267105.1:c.646A>G, XM_005267105.3:c.646A>G, XM_006715552.1:c.1222A>G, XM_011536074.1:c.646A>G, XP_005267159.1:p.Met408Val, XP_005267160.1:p.Met408Val, XP_005267161.1:p.Met216Val, XP_005267162.1:p.Met216Val, XP_006715615.1:p.Met408Val, XP_011534376.1:p.Met216Val, rs1086277, rs17202481, rs60990824
A > G
SNP
M408V
No VIP available CA VA
rs6313 NC_000013.10:g.47469940G>A, NC_000013.11:g.46895805G>A, NG_013011.1:g.6230C>T, NM_000621.4:c.102C>T, NM_001165947.2:c.160+869C>T, NP_000612.1:p.Ser34=, rs17367493, rs3742280, rs386602276, rs57425741
G > A
SNP
S34S
No VIP available No Clinical Annotations available VA
rs6785049 NC_000003.11:g.119533733G>A, NC_000003.12:g.119814886G>A, NG_011856.1:g.39403G>A, NM_003889.3:c.795-93G>A, NM_022002.2:c.912-93G>A, NM_033013.2:c.684-93G>A, XM_005247866.1:c.630-93G>A, rs58368790
G > A
SNP
No VIP available No Clinical Annotations available VA
rs707265 NC_000019.10:g.41018182A>G, NC_000019.9:g.41524087A>G, NG_007929.1:g.31884A>G, NM_000767.4:c.*1355A>G, XM_005258571.1:c.*1355A>G, XM_011526548.1:c.*1355A>G, XM_011526549.1:c.*1355A>G, XM_011526550.1:c.*1355A>G, rs28969423, rs57822270
A > G
SNP
No VIP available CA VA
rs717620 NC_000010.10:g.101542578C>T, NC_000010.11:g.99782821C>T, NG_011798.1:g.5116C>T, NM_000392.4:c.-24C>T, XM_005269536.1:c.-24C>T, XM_006717631.2:c.-24C>T, XM_011539291.1:c.-24C>T, XR_945604.1:n.166C>T, XR_945605.1:n.168C>T, rs17216163, rs386485129, rs58371376
C > T
SNP
No VIP available No Clinical Annotations available VA
rs7438284 NC_000004.11:g.69964337A>T, NC_000004.12:g.69098619A>T, NM_001074.2:c.801A>T, NP_001065.2:p.Pro267=, XM_005265702.1:c.54A>T, XM_005265702.2:c.54A>T, XM_011532229.1:c.801A>T, XM_011532230.1:c.801A>T, XM_011532231.1:c.54A>T, XP_005265759.1:p.Pro18=, XP_011530531.1:p.Pro267=, XP_011530532.1:p.Pro267=, XP_011530533.1:p.Pro18=, rs58290492
A > T
SNP
P267P
No VIP available CA VA
rs7439366 NC_000004.11:g.69964338T>C, NC_000004.12:g.69098620T>C, NM_001074.2:c.802T>C, NP_001065.2:p.Tyr268His, XM_005265702.1:c.55T>C, XM_005265702.2:c.55T>C, XM_011532229.1:c.802T>C, XM_011532230.1:c.802T>C, XM_011532231.1:c.55T>C, XP_005265759.1:p.Tyr19His, XP_011530531.1:p.Tyr268His, XP_011530532.1:p.Tyr268His, XP_011530533.1:p.Tyr19His, rs34924067, rs57980137
T > C
SNP
Y268H
No VIP available No Clinical Annotations available VA
rs762551 NC_000015.10:g.74749576C>A, NC_000015.9:g.75041917C>A, NG_008431.1:g.32035C>A, NM_000761.3:c.-9-154C>A, NM_000761.4:c.-9-154C>A, rs17861151, rs57172993
C > A
SNP
No VIP available No Clinical Annotations available VA
rs7668258 NC_000004.11:g.69962078T>C, NC_000004.12:g.69096360T>C, NM_001074.2:c.-161T>C, XM_005265702.1:c.-26-2180T>C, XM_005265702.2:c.-26-2180T>C, XM_011532229.1:c.-161T>C, XM_011532230.1:c.-161T>C, XM_011532231.1:c.-26-2180T>C, rs17551675, rs60174701
T > C
SNP
No VIP available CA VA
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
No VIP available CA VA
rs8192709 NC_000019.10:g.40991369C>T, NC_000019.9:g.41497274C>T, NG_007929.1:g.5071C>T, NM_000767.4:c.64C>T, NP_000758.1:p.Arg22Cys, XM_005258569.1:c.64C>T, XM_005258569.3:c.64C>T, XM_005258570.1:c.64C>T, XM_006723050.2:c.64C>T, XM_011526546.1:c.64C>T, XM_011526547.1:c.64C>T, XM_011526548.1:c.64C>T, XP_005258626.1:p.Arg22Cys, XP_005258627.1:p.Arg22Cys, XP_006723113.1:p.Arg22Cys, XP_011524848.1:p.Arg22Cys, XP_011524849.1:p.Arg22Cys, XP_011524850.1:p.Arg22Cys
C > T
SNP
R22C
No VIP available CA VA
rs8192719 NC_000019.10:g.41012868C>T, NC_000019.9:g.41518773C>T, NG_007929.1:g.26570C>T, NM_000767.4:c.1294+53C>T, XM_005258569.1:c.1152+383C>T, XM_005258569.3:c.1152+383C>T, XM_005258570.1:c.1153-105C>T, XM_005258571.1:c.694+53C>T, XM_006723050.2:c.1294+53C>T, XM_011526546.1:c.1205C>T, XM_011526547.1:c.1153-105C>T, XM_011526548.1:c.814+53C>T, XM_011526549.1:c.703+53C>T, XM_011526550.1:c.694+53C>T, XP_011524848.1:p.Pro402Leu, rs58710428, rs61315206
C > T
SNP
No VIP available CA VA
rs8192726 NC_000019.10:g.40848591C>A, NC_000019.9:g.41354496C>A, NG_008377.1:g.6857G>T, NM_000762.5:c.493+23G>T, XM_005258568.1:c.340+23G>T, rs61203574
C > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • EFV
  • efavirenz
Trade Names
  • Stocrin
  • Sustiva
Brand Mixture Names

PharmGKB Accession Id

PA449441

Type(s):

Drug

Description

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Source: Drug Bank

Indication

For use in combination treatment of HIV infection (AIDS)

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Similar to zidovudine, efavirenz inhibits the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). Antiviral activity of efavirenz is dependent on intracellular conversion to the active triphosphorylated form. The rate of efavirenz phosphorylation varies, depending on cell type. It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body. Even though human DNA polymerase is less susceptible to the pharmacologic effects of triphosphorylated efavirenz, this action may nevertheless account for some of the drug's toxicity.

Source: Drug Bank

Pharmacology

Efavirenz (dideoxyinosine, ddI) is an oral nucleoside reverse transcriptase inhibitor (NRTI). It is a synthetic purine derivative and, similar to zidovudine, zalcitabine, and stavudine. Efavirenz was originally approved specifically for the treatment of HIV infections in patients who failed therapy with zidovudine. Currently, the CDC recommends that Efavirenz be given as part of a three-drug regimen that includes another nucleoside reverse transcriptase inhibitor (e.g., lamivudine, stavudine, zidovudine) and a protease inhibitor or efavirenz when treating HIV infection.

Source: Drug Bank

Food Interaction

Avoid excessive or chronic alcohol consumption.|Take without regard to meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Efavirenz is principally metabolized by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive against HIV-1.

Source: Drug Bank

Protein Binding

99.5-99.75%

Source: Drug Bank

Half-Life

40-55 hours

Source: Drug Bank

Route of Elimination

Nearly all of the urinary excretion of the radiolabeled drug was in the form of metabolites.

Source: Drug Bank

Chemical Properties

Chemical Formula

C14H9ClF3NO2

Source: Drug Bank

Average Molecular Weight

315.675

Source: Drug Bank

Monoisotopic Molecular Weight

315.027390859

Source: Drug Bank

SMILES

FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1

Source: Drug Bank

InChI String

InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Efavirenz Pathway, Pharmacokinetics/Pharmacodynamics
    Schematic representation of efavirenz metabolism and mechanism of action against HIV.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Curated Information ?

EvidenceDrug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rifampin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zidovudine

Drug Interactions

Interaction Description
alprazolam - efavirenz The antiviral agent increases the effect and toxicity of benzodiazepine (source: Drug Bank )
alprazolam - efavirenz The antiviral agent increases the effect and toxicity of benzodiazepine (source: Drug Bank )
astemizole - efavirenz Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
astemizole - efavirenz Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
atazanavir - efavirenz Efavirenz decreases the levels/effects of atazanavir (source: Drug Bank )
atazanavir - efavirenz Efavirenz decreases the levels/effects of atazanavir (source: Drug Bank )
atorvastatin - efavirenz The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank )
atorvastatin - efavirenz The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank )
cisapride - efavirenz Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
cisapride - efavirenz Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
clarithromycin - efavirenz Efavirenz decreases levels of clarithromycin (source: Drug Bank )
clarithromycin - efavirenz Efavirenz decreases levels of clarithromycin (source: Drug Bank )
cyclosporine - efavirenz Efavirenz decreases the levels of cyclosporine (source: Drug Bank )
cyclosporine - efavirenz Efavirenz decreases the levels of cyclosporine (source: Drug Bank )
dihydroergotamine - efavirenz The antiretroviral agent may increase the ergot derivative (source: Drug Bank )
dihydroergotamine - efavirenz The antiretroviral agent may increase the ergot derivative (source: Drug Bank )
ergotamine - efavirenz The antiretroviral agent may increase the ergot derivative toxicity (source: Drug Bank )
ergotamine - efavirenz The antiretroviral agent may increase the ergot derivative toxicity (source: Drug Bank )
indinavir - efavirenz Efavirenz decreases the effect of indinavir (source: Drug Bank )
indinavir - efavirenz Efavirenz decreases the effect of indinavir (source: Drug Bank )
lovastatin - efavirenz The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank )
lovastatin - efavirenz The NNRT inhibitor increases the effect and toxicity of the statin (source: Drug Bank )
methadone - efavirenz The antiretroviral agent decreases the effect of methadone (source: Drug Bank )
methadone - efavirenz The antiretroviral agent decreases the effect of methadone (source: Drug Bank )
methysergide - efavirenz The antiretroviral agent may increase the ergot derivative toxicity (source: Drug Bank )
methysergide - efavirenz The antiretroviral agent may increase the ergot derivative toxicity (source: Drug Bank )
midazolam - efavirenz The antiviral agent increases the effect and toxicity of benzodiazepine (source: Drug Bank )
midazolam - efavirenz The antiviral agent increases the effect and toxicity of benzodiazepine (source: Drug Bank )
tamsulosin - efavirenz Efavirenz, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Efavirenz is initiated, discontinued, or dose changed. (source: Drug Bank )
tamsulosin - efavirenz Efavirenz, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Efavirenz is initiated, discontinued, or dose changed. (source: Drug Bank )
telithromycin - efavirenz Efavirenz may decrease the plasma concentration of Telithromycin. Consider alternate therapy. (source: Drug Bank )
terfenadine - efavirenz Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
terfenadine - efavirenz Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
tipranavir - efavirenz Efavirenz may alter the serum concentration Tipranavir. Monitor for changes in Tipranavir therapeutic and adverse effects if Efavirenz is initiated, discontinued or dose changed. (source: Drug Bank )
tolterodine - efavirenz Efavirenz may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank )
tolterodine - efavirenz Efavirenz may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank )
tramadol - efavirenz Efavirenz may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. (source: Drug Bank )
trazodone - efavirenz The CYP3A4 inhibitor and inducer, Efavirenz, may alter Trazodone efficacy/toxicity by altering Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Efavirenz is initiated, discontinued or dose changed. (source: Drug Bank )
trazodone - efavirenz The CYP3A4 inhibitor and inducer, Efavirenz, may alter Trazodone efficacy/toxicity by altering Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Efavirenz is initiated, discontinued or dose changed. (source: Drug Bank )
triazolam - efavirenz The antiviral agent increases the effect and toxicity of benzodiazepine (source: Drug Bank )
triazolam - efavirenz The antiviral agent increases the effect and toxicity of benzodiazepine (source: Drug Bank )
voriconazole - efavirenz Efavirenze may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of efavirenz by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased efavirenz adverse effects during concomitant therapy. (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to efavirenz: 145

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV. CPT: pharmacometrics & systems pharmacology. 2016. Hui K H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. British journal of clinical pharmacology. 2016. Bienczak Andrzej, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. BMC infectious diseases. 2016. Pinillos Francoise, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Efavirenz pharmacogenetics in a cohort of Italian patients. International journal of antimicrobial agents. 2015. Cusato Jessica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genotype-guided dose adjustment for the use of efavirenz in HIV treatment. The Journal of infection. 2015. Lam Tai Ning, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015. Luetkemeyer Anne F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: Efavirenz pathway, pharmacokinetics. Pharmacogenetics and genomics. 2015. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. Clinical pharmacology and therapeutics. 2015. Olagunju A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in south Africa. British journal of clinical pharmacology. 2015. Sinxadi Phumla Z, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities. Current opinion in HIV and AIDS. 2015. Haas David W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. Frontiers in genetics. 2015. Swart Marelize, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study. Pharmacogenomics and personalized medicine. 2015. Damronglerd Pansachee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand. Pharmacogenomics and personalized medicine. 2015. Bushyakanist Asalaysa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenetics and genomics. 2014. Lehmann David S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic Variability of CYP2B6 Polymorphisms in Southeast Iranian Population: Implications for Malaria and HIV/AIDS Treatment. Archives of Iranian medicine. 2014. Zakeri Sedigheh, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. Pharmacogenomics. 2014. Mukonzo Jackson K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4beta-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. The Journal of antimicrobial chemotherapy. 2014. Ngaimisi E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Pharmacogenomics. 2014. Martín Almudena Sánchez, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1. Antimicrobial agents and chemotherapy. 2014. Manosuthi Weerawat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?. International journal of clinical pharmacology and therapeutics. 2014. Liu Jiang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti. The Journal of antimicrobial chemotherapy. 2014. Haas David W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. The Journal of antimicrobial chemotherapy. 2014. Haas David W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. Antiviral research. 2014. Bienvenu Emile, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. The Journal of infectious diseases. 2014. Bertrand Julie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. Antimicrobial agents and chemotherapy. 2014. Salem Ahmed Hamed, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EMA Initiatives and Perspectives on Pharmacogenomics. British journal of clinical pharmacology. 2014. Ehmann Falk, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults. Drug metabolism and pharmacokinetics. 2014. Sukasem Chonlaphat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. European journal of clinical pharmacology. 2014. Naidoo Panjasaram, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. Journal of clinical pharmacology. 2014. Abdelhady A M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug metabolism and disposition: the biological fate of chemicals. 2013. Xu Cong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes. PloS one. 2014. Mukonzo Jackson K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. PloS one. 2014. Lee Kuan-Yeh, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interleukin-10 gene polymorphism (-1082G/A) and allergy to efavirenz in patients infected with human immunodeficiency virus. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2014. Rodrigues Raphael de Oliveira, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism. Infection. 2013. Sukasem C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe. Current HIV research. 2013. Dhoro Milcah, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. The Journal of antimicrobial chemotherapy. 2013. Sarfo Fred S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Mitochondrial DNA Variation and Changes in Adiponectin and Endothelial Function in HIV-Infected Adults After Antiretroviral Therapy Initiation. AIDS research and human retroviruses. 2013. Hulgan Todd, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients. Journal of clinical pharmacology. 2013. Coelho Antonio V C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms. International journal of STD & AIDS. 2013. Lee Shui Shan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics. 2013. Sánchez Martín Almudena, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenetics and genomics. 2013. Swart Marelize, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools. Human mutation. 2013. Radloff Robert, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. The pharmacogenomics journal. 2013. Michaud V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. Antimicrobial agents and chemotherapy. 2013. Manosuthi Weerawat, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Therapeutic drug monitoring. 2013. Cortes Claudia P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC infectious diseases. 2013. Mukonzo Jackson K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. British journal of clinical pharmacology. 2012. Sukasem Chonlaphat, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections. Drug metabolism and pharmacokinetics. 2013. Sukasem Chonlaphat, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Single-Nucleotide Polymorphism in CYP2B6 Leads to >3-Fold Increases in Efavirenz Concentrations in Plasma and Hair Among HIV-Infected Women. The Journal of infectious diseases. 2012. Gandhi Monica, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenetics and genomics. 2012. Holzinger Emily R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics. 2012. Olagunju Adeniyi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. The pharmacogenomics journal. 2012. Habtewold A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological reviews. 2012. Michaud Veronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl-metabolites: exploration of a novel CYP2B6 phenotyping index. British journal of clinical pharmacology. 2012. Jiang Fen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HIV-1 antiretroviral drug therapy. Cold Spring Harbor perspectives in medicine. 2012. Arts Eric J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. European journal of clinical pharmacology. 2012. Viljoen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans. HIV medicine. 2012. Nanzigu S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenetics and genomics. 2012. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clinical pharmacology and therapeutics. 2012. Michaud V, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals. Therapeutic drug monitoring. 2012. Heil Sandra G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC medical genetics. 2012. Swart Marelize, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. Molecules (Basel, Switzerland). 2012. Ji Hye Young, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. The Journal of antimicrobial chemotherapy. 2011. Habtewold Abiy, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. The Journal of antimicrobial chemotherapy. 2011. Wyen Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. The Journal of pharmacology and experimental therapeutics. 2011. Zhang Haoming, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. Clinical pharmacology and therapeutics. 2011. Ngaimisi E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. The pharmacogenomics journal. 2011. Yimer G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica; the fate of foreign compounds in biological systems. 2011. Bae S K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrobial agents and chemotherapy. 2011. Cho Doo-Yeoun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. Journal of acquired immune deficiency syndromes (1999). 2010. Svärd Jenny, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. 2011. Grady Benjamin J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. The Journal of antimicrobial chemotherapy. 2010. Jamshidi Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clinical pharmacology and therapeutics. 2010. Ngaimisi E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrobial agents and chemotherapy. 2010. Burhenne Jürgen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Therapeutic drug monitoring. 2010. Chen Jun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. Therapeutic drug monitoring. 2010. Cabrera Figueroa Salvador, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics. 2010. Elens Laure, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. The Journal of infectious diseases. 2010. Ribaudo Heather J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug metabolism and disposition: the biological fate of chemicals. 2010. Ogburn Evan T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2010. Soyinka Julius Olugbenga, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antiretrovirals. Antiviral research. 2010. Tozzi Valerio. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert opinion on drug metabolism & toxicology. 2010. Kwara Awewura, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efavirenz in the therapy of HIV infection. Expert opinion on drug metabolism & toxicology. 2010. Rakhmanina Natella Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS research and therapy. 2010. Uttayamakul Sumonmal, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS research and therapy. 2010. Gounden Verena, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV. Clinical drug investigation. 2010. Cabrera Figueroa Salvador, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. British journal of clinical pharmacology. 2009. Mukonzo Jackson K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS (London, England). 2009. Kwara Awewura, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer chemotherapy and pharmacology. 2009. Jeong Seongwook, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population. Drug metabolism and disposition: the biological fate of chemicals. 2009. Davaalkham Jagdagsuren, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Current drug metabolism. 2009. Mo Sui-Lin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug metabolism and disposition: the biological fate of chemicals. 2009. Bélanger Anne-Sophie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation. HIV medicine. 2009. Powers Vicki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. The Journal of infectious diseases. 2009. Leger Paul, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clinical pharmacology and therapeutics. 2009. Arab-Alameddine M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. British journal of clinical pharmacology. 2009. Kwara Awewura, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and genomics. 2009. di Iulio Julia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. The Journal of infectious diseases. 2009. Haas David W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin-antiretroviral interactions. The Annals of pharmacotherapy. 2009. Liedtke Michelle D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antiviral therapy. 2009. Cohen Karen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Current drug metabolism. 2008. Wang Hongbing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. Journal of clinical pharmacology. 2008. Kwara Awewura, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of antiretrovirals. Recent patents on anti-infective drug discovery. 2008. Roca Bernardino. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antiretroviral agents. Current opinion in HIV and AIDS. 2008. Owen Andrew, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. The Journal of antimicrobial chemotherapy. 2008. Wyen Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. The Journal of pharmacology and experimental therapeutics. 2008. Hofmann Marco H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS (London, England). 2008. Vitezica Zulma G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clinical pharmacology and therapeutics. 2008. Fletcher C V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antiviral therapy. 2008. ter Heine Rob, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007. Gatanaga Hiroyuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. British journal of clinical pharmacology. 2007. Mehlotra Rajeev K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. Journal of acquired immune deficiency syndromes (1999). 2007. Saitoh Akihiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007. Desta Zeruesenay, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clinical pharmacology and therapeutics. 2007. Rotger M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. The Journal of pharmacology and experimental therapeutics. 2007. Faucette Stephanie R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clinical pharmacology and therapeutics. 2006. Colombo Sara, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006. Ritchie Marylyn D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?. Therapeutic drug monitoring. 2006. Colombo Sara, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenetics and genomics. 2006. Wang Jue, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. British journal of clinical pharmacology. 2006. Burger David, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006. Nolan David, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006. Ribaudo Heather J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenetics and genomics. 2005. Klein Kathrin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. The Journal of infectious diseases. 2005. Haas David W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overview of the pharmacogenetics of HIV therapy. The pharmacogenomics journal. 2006. Rodríguez-Nóvoa S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2005. Rodriguez-Novoa Sonia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and genomics. 2005. Rotger Margalida, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (London, England). 2004. Haas David W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. Journal of clinical pharmacology. 2004. Hariparsad Niresh, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochemical and biophysical research communications. 2004. Tsuchiya Kiyoto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Therapeutic drug monitoring. 2004. Ståhle Lars, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. European journal of medical research. 2003. Winzer Ralf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. The Journal of pharmacology and experimental therapeutics. 2003. Ward Bryan A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clinical pharmacology and therapeutics. 2003. Csajka Chantal, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002. Fellay Jacques, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS (London, England). 2001. Marzolini C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug metabolism and disposition: the biological fate of chemicals. 1999. Mutlib A E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efavirenz. Drugs. 1998. Adkins J C, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0056-0474-92
DrugBank:
DB00625
PDB:
EFZ
Chemical Abstracts Service:
154598-52-4
ChEBI:
119486
KEGG Compound:
C08088
KEGG Drug:
D00896
PubChem Compound:
64139
PubChem Substance:
206181
46506827
Drugs Product Database (DPD):
2246045
BindingDB:
2483
ChemSpider:
57715
HET:
EFZ
Therapeutic Targets Database:
DAP000709
FDA Drug Label at DailyMed:
32d6371e-ba56-4294-b732-6d43627c5c47

Clinical Trials

These are trials that mention efavirenz and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.